Structures by: Sasaki A.
Total: 6
Furosemide nicotinamide 1:1 cocrystal form II
C12H11ClN2O5S,C6H6N2O
Crystal Growth & Design (2012) 12, 1 485
a=16.4686(4)Å b=5.01253(14)Å c=24.7963(7)Å
α=90° β=108.8400(6)° γ=90°
Furosemide nicotinamide 1:1 cocrystal form I
C12H11ClN2O5S,C6H6N2O
Crystal Growth & Design (2012) 12, 1 485
a=4.86286(13)Å b=20.7109(6)Å c=19.3632(5)Å
α=90° β=92.4168(6)° γ=90°
Furosemide nicotinamide 1:1 cocrystal form III
C12H11ClN2O5S,C6H6N2O
Crystal Growth & Design (2012) 12, 1 485
a=5.22828(4)Å b=18.71272(17)Å c=20.12138(18)Å
α=90° β=94.8246(5)° γ=90°
Furosemide nicotinamide 1:1 cocrystal form IV
C12H11ClN2O5S,C6H6N2O
Crystal Growth & Design (2012) 12, 1 485
a=40.6357(13)Å b=5.36051(15)Å c=18.3727(5)Å
α=90° β=92.5034(13)° γ=90°
Furosemide nicotinamide 1:1 cocrystal hydrate
C12H11ClN2O5S,C6H6N2O,2(H2O)
Crystal Growth & Design (2012) 12, 1 485
a=46.9784(16)Å b=5.09800(15)Å c=18.1866(6)Å
α=90.0000° β=92.5680(18)° γ=90.0000°
Kamiokite
Fe2Mo3O8
Acta Crystallographica, Section C (1986) 42, 9-11
a=5.781Å b=5.781Å c=10.060Å
α=90° β=90° γ=120°